Codexis, Inc. (CDXS)
CDXSNASDAQ-GSMajor Chemicals
$1.02
-0.0950 (-8.56%) today
Regular session, Nov 10, 3:17 PM ET
- Market cap
- $111.15m
- P/E
- –
- EPS, last 4 quarters
- $-0.3400
- Dividend yield
- –
- Day range
- $1.01 to $1.14
- 52-week range
- $0.9583 to $2.98
- Average volume
- 839.3k
- Previous close
- $1.11
Analysts
4 coveringBuy3 buy, 1 hold, 0 sell
Targets a year out average $6.50, +540.4% from here
Earnings
next estimate $-0.0900Next report Nov 12, 2026
Sep 2025
-46.7%
Dec 2025
+1000.0%
Mar 2026
+9.1%
Jun 2026
+23.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $8.60m | $38.91m | $15.25m | $14.91m |
| Gross profit | $6.14m | $36.87m | $13.18m | $11.40m |
| Operating income | -$18.95m | $10.56m | -$8.04m | -$11.23m |
| Net income | -$19.61m | $9.60m | -$8.70m | -$12.01m |
Last four quarters: revenue $77.68m, margin -39.5%, free cash flow -$12.18m
News
8 latest- Codexis Presents Data Validating ECO Synthesis For SiRNA Production; Secures $60 Mln Loan Facility RTTNews · 4 hours ago
- Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue EstimatesZacks · 7 hours ago
- Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data RTTNews · Oct 2, 2026
- Codexis Partners With SiRNA Drug Developer To Advance Next-Generation RNA Manufacturing RTTNews · Sep 28, 2026
- Codexis (CDXS) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 18, 2026
- Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Aug 14, 2026
The company
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.
- Sector
- Industrials
- Industry
- Major Chemicals
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- codexis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.